Phase I study of CBA-1535

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210708

Enrollment

Registered

2022-03-30

Start date

2022-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor (standard therapy is not available, non-responder or intolerable)

Interventions

Part 1: Dose escalation

CBA-1535 (single agent therapy) Part 2: Dose escalation

CBA-1535 + pembrolizumab (combination therapy)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - ECOG performance status: <= 1 - Patients with 3 months or longer life expectancy

Exclusion criteria

Exclusion criteria: - Patients who received other investigational drug or antibody drugs, including immune checkpoint inhibitor within 28 days prior to enrollment - Patients who received anti-cancer drug within 14 days prior to enrollment

Design outcomes

Primary

Measure	Time frame
- Dose Limiting Toxicity - Adverse Event	—

Contacts

Public ContactMiseri Tanaka

Chiome Bioscience Inc.

ir@chiome.co.jp+81-3-6383-3561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026